Sunovion's Latuda wins FDA nod for bipolar depression

07/2/2013 | Pharmaceutical Business Review Online

Sunovion Pharmaceuticals obtained the FDA's approval to market Latuda, or lurasidone, as a monotherapy and in combination with either lithium or valproate in adults with bipolar depression. The approval was based on favorable data from two double-blind studies.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC